Connection

Andrew Kraft to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Drug Resistance, Neoplasm.
Andrew Kraft
Connection Strength
1.316
Drug Resistance, Neoplasm
  1. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther. 2018 12; 17(12):2710-2721.
    View in: PubMed
    Score: 0.534
  2. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
    View in: PubMed
    Score: 0.168
  3. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. Mol Cancer Ther. 2020 09; 19(9):1809-1821.
    View in: PubMed
    Score: 0.152
  4. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res. 2018 01 01; 24(1):169-180.
    View in: PubMed
    Score: 0.126
  5. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 2017 May 02; 8(18):30199-30216.
    View in: PubMed
    Score: 0.122
  6. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
    View in: PubMed
    Score: 0.110
  7. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015 Jul; 151:41-9.
    View in: PubMed
    Score: 0.105
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.